Experience with Interferon in Chronic Hepatitis B in Egypt

References

• Schalm SW, Summerskill WHJ, Gitnick GL, Elveback LR. Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis B s antigen. Gut, 1976; 17: 781–786.
   Google Scholar
• Lam KC, Lai CL, Ng RP, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg positive chronic active hepatitis. N Engl J Med, 1981; 304: 380–386.
   Google Scholar
• Wu PC, Lai CL, Lam KC, Ho J. Prednisolone in HBsAg-positive chronic active hepatitis: Histologic evaluation in a controlled prospective study. Hepatology, 1982; 2: 777–783.
   Google Scholar
• Bahgat MH, Sabbour MS, Osman LM, Ghali AF, Gadallah MA. Comparative Study of different types of treatment in chronic active hepatitis. Chemioterapia 1985; 4, 227–235.
   Google Scholar
• Tanno H, Fay OH, Rojman JA, Palazzi J, Bessone F. HBeAg/anti-HBe seroconversion during and after protracted immunosuppressive treatment in type B chronic hepatitis. In: Zuckerman AJ, (ed): Viral Hepatitis and Liver Disease. New York, Alan R Liss, Inc., 1988: 940–943.
   Google Scholar
• Shulman ST, Hutto JH, Ayoub EM, Howlett SA, Scott B, McGuigan JE. A double blind evaluation of transfer factor therapy in HBsAg positive chronic aggressive hepatitis: preliminary report of efficacy. Cell Immunol 1979; 43: 352–361.
   Google Scholar
• Nilius R, Schentke U, Otto L, et al. Levamisole therapy in chronic hepatitis B: Results of a multicentric double blind trial. Hepatogastroenterology, 1983; 30: 90–92.
   Google Scholar
• Scully LJ, Lloyd C, Karayiannis P, Thomas HC. Clinical and immunological response of chronic hepatitis B virus carriers to 0-palmitoyl-3( + )-catechin. Hepatology 1988; 8: 1322.
   Google Scholar
• MacGilchrist AJ, Follet E. Bacillus-Calmette-Guerin vaccine as immunotherapy in chronic hepatitis B. In: Zuckerman AJ, (ed): Viral Hepatitis and Liver Disease. New York, Alan R Liss, Inc., 1988; 963–964.
   Google Scholar
• Jain S, Thomas HC, Oxford JS, Sherlock S. Trial of ribavirin for the treatment of HBsAg positive chronic liver disease. Antimicrob Chemother 1978; 4: 367–373.
   Google Scholar
• Hoofnagle JH, Hanson RG, Minuk GY, et al. Randomised controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 1984; 86: 150–157.
   Google Scholar
• Weller IVD, Carraro V, Fowler MJF, Monjardino J, Makinen D, Thomas HC, Sherlock S. Acyclovir in hepatitis B e antigen positive chronic liver disease: Inhibition of viral replication and transient renal impairment with I.V. bolus administration. Antimicrob Chemother 1983; 11: 223–231.
   Google Scholar
• Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Marigan TC. Effect of human leucocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295: 517–522.
   Google Scholar
• Smith CI, Weissberg J, Bernhardt L, Gregory PB, Robinson WS, Merigan TC. Acute Dane particle suppression with recombinant leucocyte A interferon in chronic hepatitis B. J Infect Dis 1983; 148: 907–913.
   Google Scholar
• Lok ASF, Weller IVD, Karayiannis P. et al. Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver, 1989; 4: 45–49.
   Google Scholar
• Ornata M, Imazeki F, Yokosuka O, Ito Y, Uchiumi K, Mori J, Okuda K. Recombinant leucocyte A interferon treatment in patients with chronic hepatitis B virus infection. Pharamacokinetics, tolerance, and biological effects. Gastroenterology, 1985; 88: 870–880.
   Google Scholar
• Scully LJ, Shein R, Karayiannis P, McDonald JA, Thomas HC. A randomised trial of 12 versus 24 weeks of lymphoblastoid interferon (Wellferon) in the treatment of chronic hepatitis B virus infection. Hepatology, 1986; 6: 1149.
   Google Scholar
• Dooley JS, Davis GL, Peters M, Waggoner JG, Goodman Z, Hoofnagle JH. Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. Gastroenterlogy 1986; 90: 150–157.
   Google Scholar
• Lok ASF, Lai CL, Wu PC. A randomised controlled trial of recombinant ±-2 interferon in chronic hepatitis B virus (HBV) infection. Hepatology, 1986; 6: 1123.
   Google Scholar
• Lai CL, Lok ASF, Lin HJ, Wu PC, Yeung CY, Yeoh EK, Chang WK. The effect of recombinant α-2 interferon in Chinese HBsAg carrier children: a randomised pilot study. Hepatology, 1986; 6: 1123.
   Google Scholar
• Dusheiko GM, Di Bisceglie A, Bowyer S, Sachs E, Ritchie M, Schoub B, Kew M. Recombinant leucocyte interferon treatment of chronic hepatitis B. Hepatology, 1985; 5: 556–560.
   Google Scholar
• Ghaffar YA. Chronic active hepatitis in Egypt. In: Ghaffar YA, (ed): Liver Diseases: The Egyptian Experience. Cairo, Society of friends of liver patients in the Arab world, in cooperation with United Nations Development Program (Publishers), 1984; 97–111.
   Google Scholar
• Bianchi L. Spichtin Hp, Gudat F. Chronic hepatitis In: Macsween RNM, Anthony PP, and Scheuer PJ, (eds): Pathology of the Liver, (second edition). Edinburgh, Churchill Livingstone, 1987; 310–341.
   Google Scholar
• Lok ASF, Lai CL, Wu PC, Leung EK. A randomised controlled trial of recombinant α – 2 interferon in Chinese patients with chronic hepatitis B virus infection. An interim report. In: Zuckerman AJ, (ed): Viral Hepatitis and Liver Disease. New York, Alan R Liss, Inc. 1988: 848–849.
   Google Scholar
• Lai CL, Lok ASF, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Effect of recombinant alpha 2 – interferon in Chinese hepatitis B surface antigen carrier children: a prospective controlled trial. In: Zuckerman AJ, (ed): Viral Hepatitis and Liver Disease. New York, Alan R Liss, Inc., 1988: 850.
   Google Scholar
• Dusheiko GM, Kassianides C, Song E, Pitcher L, Ryff J, Sjogren M, Kew MC. Loss of hepatitis B surface antigen in three controlled trials of recombinant alpha-interferon for treatment of chronic hepatitis B. In: Zuckerman AJ, (ed): Viral Hepatitis and Liver Disease. New York, Alan R Liss, Inc., 1988: 844–847.
   Google Scholar
• Scully LJ, SHein R, Lok ASF, Karayiannis P, Thomas HC. Lymphoblastoid interferon therapy of chronic hepatitis B virus infection. Clin Invest 1985; 8: A92.
   Google Scholar
• Scully LJ, SHein R, Lok ASF, Karayiannis P, Thomas HC. Lymphoblastoid interferon therapy of chronic hepatitis B virus infection — different racial responses. J Hepatol 1985; 2: 328.
   Google Scholar
• Scully LJ, Shein R, Lok ASF, Thomas HC. Factors determining response rate to antiviral therapy in chronic hepatitis B infection. J Hepatol 1985; 2: 328.
   Google Scholar
• Barbara L, Mazzella G, Baraldini M, et. al. A randomised controlled trial with human lymphoblastoid interferon vs no treatment in chronic hepatitis B virus infection. J Hepatol, 1986; 3: S235–S238.
   Google Scholar
• Mazzella G, Villanova N, Abdu-Ahmed M, et al. Treatment of hepatitis B with human lymphoblastoid interferon: Results of a controlled trial. Chemioterapia, 1988; 7 (suppl. 3): 12–14.
   Google Scholar
• Perez V, Tanno H, Fay O, Barklay CA. Treatment of chronic active herpatitis B (CAHB) with r-IFN-alpha-A. J Med Virol, 1987; 21: 122A.
   Google Scholar
• Williams SJ, Farrell GC, Batey RG, Bye WA. Sydney interferon trial for chronic active hepatitis B. Aust N Z J Med, 1986; 16: 596.
   Google Scholar
• Carrero V, Porres JC, Gutiez J, Reguera JI, Quiroga JA, Marron JA, Hernandez GC. Long term treatment of hepatitis B virus (HBV) infection with recombinant leucocyte A interferon (rIFN-alpha A): A pilot study. Antiviral Res Abstr 1984; 1: 101.
   Google Scholar
• Mora I, Porres JC, Bartolome J, et al. Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection. J Hepatol 1987; 4: 29–36.
   Google Scholar
• Chu CM, Karayiannis P, Fowler MJF, Monjardino J, Liaw YF, Thomas HC. Natural history of chronic hapatitis B virus infection in Taiwan: Studies of hepatitis B virus DNA in serum. Hepatology 1985; 5: 432–434.
   Google Scholar
• Chu CM, Liaw YF, Sheen IS, CHen TJ. Correlation of age with the status of hepatitis B virus replication and histological changes in chronic type B hepatitis. Liver, 1985; 5: 117–122.
   Google Scholar
• Beasley RP, Hwang LY, Lin CC, et al. Hepatitis B immune globulin (HBIG) efficacy on the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised. Lancet, 1981; 2: 388–393.
   Google Scholar
• Papaevangelou G, Hoofnagle JH. Tansmission of hepatitis B virus infection by asymptomatic chronic HBsAg carrier mothers. Pediatrics 1979; 63: 602–605.
   Google Scholar
• Basalamah AH, Serebour F, Karim E. Maternofetal transmission of hepititis B in Saudi Arabia. J Infect 1984; 8: 200–204.
   Google Scholar
• Hyams KC, Osman NM, Khaled EM, et al. Maternal infant transmission of hepatitis B in Egypt. In: Zuckerman AJ, (ed): viral Hepatitis and Liver Disease. New York, Alan R Liss, Inc., 1988: 170–173.
   Google Scholar
• Realdi G, Alberti A, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, Ruol A. Seroconversion from hepatitis B c antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980; 79: 195–199.
   Google Scholar
• Hoofnagle JH, Dusheiko GM, Seef LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B ’e’ antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 744–748.
   Google Scholar
• Lindh G, Weiland O, Svedmyr A, Gaumann H, Hansson BG. Long term follow-up of 60 patients with chronic hepatitis B. I. Seroconversion in the hepatitis B e-system, frequency of Delta infection and histological outcome. Liver, 1986; 6: 7–12.
   Google Scholar
• Fattovich G, Rugge M, Brollo L, et al. Clinical, virological and histological outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis B. Hepatology 1986; 6: 167–172.
   Google Scholar
• Liaw YF, Chu CM, Su I, Huang MJ, Lin DY, Chiang-Chien CS. Clinical and histological events preceding hepatitis Be antigen seroconversion in chronic type B hepatitis. Gastroenterology, 1983; 84: 216–219.
   Google Scholar
• Alexander GJM, Fagan EA, Guarner P, Rolando N, Brahm J, Eddleston ALWF, Williams R. A controlled trial of 6 months thrice weekly lymphoblastoid interferon versus no therapy in chronic hepatitis B virus infection. J Hepatol, 1986; 3: S183–S188.
   Google Scholar
• Pignatelli M, Waters J, Brown D, et al. HLA class I antigens on the hepatocyte membranes during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology 1986; 6: 349–353.
   Google Scholar
• Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985; 89: 732–735.
   Google Scholar
• Rakela J, Czaja AJ, Taswell HF, Bowyer BA, Lange SM, Anderson ML. Long term treatment with recombinant leucocyte A interferon (Roferon A) in patients with chronic hepatitis B. Hepatology 1988; 8: 1268.
   Google Scholar
• De Groote J, Fevery J, Lepontre L. Long term follow up of chronic hepatitis of moderate severity. Gut, 1978; 19: 510–513.
   Google Scholar
• Matsumara N, Yoshikawa T, Kawakami H, Kishida T. Therapeutic effect of low dosage of human leucocyte interferon on chronic hepatitis B virus infection. Digestion 1983; 26: 205–212.
   Google Scholar
• Okuno T, Shindo M, Arai K, Matsumoto M, Takeda M, Takino T, Sokawa Y. Changes of intrahepatic localisation of hepatitis B core antigens and histological activity in chronic hepatitis B before and after interferon treatment. Hepatology 1988; 8: 1406.
   Google Scholar
• Lok ASF, Hadziyannis SJ, Weller IVD, et al. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25: 1283–1287.
   Google Scholar
• Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. N Engl J Med, 1981; 305: 1067–1073.
   Google Scholar